| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 49 | 2024 | 4147 | 5.150 |
Why?
|
| Oropharyngeal Neoplasms | 20 | 2023 | 1161 | 4.950 |
Why?
|
| Carcinoma, Squamous Cell | 39 | 2024 | 5593 | 4.060 |
Why?
|
| Papillomavirus Infections | 13 | 2024 | 999 | 2.650 |
Why?
|
| Veterans | 14 | 2023 | 1737 | 2.540 |
Why?
|
| Laryngeal Neoplasms | 8 | 2023 | 529 | 2.480 |
Why?
|
| Metformin | 8 | 2023 | 393 | 2.230 |
Why?
|
| Osteoradionecrosis | 3 | 2023 | 128 | 1.700 |
Why?
|
| Fibroblasts | 13 | 2011 | 1654 | 1.540 |
Why?
|
| Laryngectomy | 7 | 2023 | 243 | 1.520 |
Why?
|
| Dinoprostone | 11 | 2022 | 219 | 1.460 |
Why?
|
| Mouth | 3 | 2021 | 125 | 1.420 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 7 | 2021 | 291 | 1.400 |
Why?
|
| Wound Healing | 16 | 2019 | 749 | 1.260 |
Why?
|
| Thyroid Neoplasms | 10 | 2021 | 1894 | 1.240 |
Why?
|
| Lactic Acid | 4 | 2018 | 310 | 1.170 |
Why?
|
| Hypoglycemic Agents | 5 | 2021 | 599 | 1.110 |
Why?
|
| Deglutition Disorders | 3 | 2019 | 489 | 1.060 |
Why?
|
| Mouth Neoplasms | 4 | 2022 | 734 | 1.060 |
Why?
|
| Papillomaviridae | 7 | 2022 | 636 | 0.980 |
Why?
|
| Glottis | 7 | 2019 | 68 | 0.970 |
Why?
|
| Antineoplastic Agents | 13 | 2024 | 14617 | 0.880 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2023 | 42 | 0.860 |
Why?
|
| Tumor Suppressor Protein p53 | 11 | 2024 | 3658 | 0.830 |
Why?
|
| Pyruvic Acid | 5 | 2018 | 132 | 0.800 |
Why?
|
| Gastrostomy | 2 | 2019 | 196 | 0.750 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2021 | 57 | 0.740 |
Why?
|
| Risk Assessment | 6 | 2019 | 6764 | 0.720 |
Why?
|
| CD8 Antigens | 2 | 2020 | 174 | 0.700 |
Why?
|
| Cisplatin | 7 | 2024 | 2497 | 0.680 |
Why?
|
| Veterans Health | 1 | 2021 | 174 | 0.680 |
Why?
|
| Humans | 109 | 2024 | 270740 | 0.680 |
Why?
|
| Cell Movement | 9 | 2014 | 2472 | 0.670 |
Why?
|
| Laryngostenosis | 5 | 2014 | 36 | 0.630 |
Why?
|
| Free Tissue Flaps | 6 | 2024 | 374 | 0.630 |
Why?
|
| Oxidative Phosphorylation | 1 | 2020 | 271 | 0.620 |
Why?
|
| Retrospective Studies | 35 | 2024 | 39890 | 0.620 |
Why?
|
| Biomarkers, Tumor | 12 | 2023 | 10708 | 0.620 |
Why?
|
| Voice Quality | 1 | 2018 | 35 | 0.610 |
Why?
|
| Larynx, Artificial | 1 | 2018 | 44 | 0.590 |
Why?
|
| Deoxyglucose | 3 | 2012 | 120 | 0.580 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2023 | 256 | 0.580 |
Why?
|
| Cell Line, Tumor | 22 | 2024 | 14849 | 0.570 |
Why?
|
| Carbon Isotopes | 3 | 2015 | 363 | 0.570 |
Why?
|
| Carbon | 1 | 2018 | 165 | 0.560 |
Why?
|
| Mandible | 3 | 2023 | 191 | 0.540 |
Why?
|
| Chemoradiotherapy | 6 | 2018 | 2027 | 0.530 |
Why?
|
| Reactive Oxygen Species | 5 | 2017 | 1005 | 0.520 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 172 | 0.510 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 3035 | 0.510 |
Why?
|
| Vocal Cords | 5 | 2020 | 105 | 0.500 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2019 | 600 | 0.490 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2022 | 506 | 0.480 |
Why?
|
| Radiation Tolerance | 3 | 2015 | 639 | 0.470 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2016 | 232 | 0.460 |
Why?
|
| Collagen | 7 | 2011 | 727 | 0.460 |
Why?
|
| Smoking | 3 | 2020 | 2555 | 0.460 |
Why?
|
| Disease Management | 1 | 2019 | 1090 | 0.450 |
Why?
|
| Prognosis | 16 | 2023 | 22505 | 0.440 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 14012 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2023 | 10400 | 0.430 |
Why?
|
| Mice, Nude | 10 | 2023 | 4329 | 0.430 |
Why?
|
| Time-to-Treatment | 4 | 2024 | 307 | 0.430 |
Why?
|
| Middle Aged | 37 | 2024 | 90352 | 0.420 |
Why?
|
| Interleukin-1beta | 4 | 2012 | 294 | 0.420 |
Why?
|
| Salvage Therapy | 3 | 2023 | 2123 | 0.420 |
Why?
|
| Male | 47 | 2024 | 128315 | 0.420 |
Why?
|
| Disease-Free Survival | 11 | 2021 | 10265 | 0.420 |
Why?
|
| Carcinoma | 6 | 2023 | 2610 | 0.410 |
Why?
|
| Oxidative Stress | 2 | 2018 | 1149 | 0.400 |
Why?
|
| Rabbits | 10 | 2012 | 1028 | 0.390 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2024 | 2271 | 0.390 |
Why?
|
| Glucose | 2 | 2023 | 1218 | 0.380 |
Why?
|
| Neoplasm, Residual | 3 | 2018 | 1754 | 0.380 |
Why?
|
| Glycolysis | 5 | 2018 | 530 | 0.380 |
Why?
|
| Aged | 30 | 2024 | 73333 | 0.370 |
Why?
|
| Female | 44 | 2024 | 148940 | 0.370 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2024 | 5408 | 0.370 |
Why?
|
| Mutant Proteins | 1 | 2011 | 234 | 0.360 |
Why?
|
| Combined Modality Therapy | 9 | 2023 | 9039 | 0.340 |
Why?
|
| Survival Analysis | 7 | 2020 | 9292 | 0.340 |
Why?
|
| Mucous Membrane | 4 | 2012 | 263 | 0.330 |
Why?
|
| Animals | 31 | 2024 | 61956 | 0.320 |
Why?
|
| Mutation | 5 | 2018 | 15912 | 0.320 |
Why?
|
| Neoplasms | 7 | 2023 | 15927 | 0.320 |
Why?
|
| Glutamine | 1 | 2011 | 324 | 0.320 |
Why?
|
| Lymph Nodes | 3 | 2018 | 3077 | 0.310 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 12033 | 0.310 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 1024 | 0.300 |
Why?
|
| Quality of Life | 3 | 2022 | 4761 | 0.300 |
Why?
|
| Follow-Up Studies | 10 | 2021 | 15218 | 0.300 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2453 | 0.300 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2024 | 7895 | 0.290 |
Why?
|
| Mice | 17 | 2024 | 35600 | 0.280 |
Why?
|
| Trachea | 1 | 2009 | 298 | 0.280 |
Why?
|
| Keloid | 1 | 2007 | 14 | 0.280 |
Why?
|
| Mitochondria | 4 | 2020 | 1297 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 5 | 2021 | 4048 | 0.270 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2023 | 497 | 0.270 |
Why?
|
| Cohort Studies | 8 | 2022 | 9470 | 0.270 |
Why?
|
| Risk | 2 | 2021 | 1939 | 0.270 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 2 | 2023 | 118 | 0.260 |
Why?
|
| Radiation, Ionizing | 3 | 2015 | 190 | 0.260 |
Why?
|
| Lymphatic Metastasis | 5 | 2024 | 4963 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 9042 | 0.240 |
Why?
|
| Precision Medicine | 2 | 2023 | 1207 | 0.240 |
Why?
|
| United States | 9 | 2024 | 15861 | 0.240 |
Why?
|
| Lip Neoplasms | 1 | 2024 | 20 | 0.230 |
Why?
|
| Glossectomy | 2 | 2021 | 43 | 0.230 |
Why?
|
| Mammary Analogue Secretory Carcinoma | 1 | 2023 | 8 | 0.230 |
Why?
|
| Tongue Neoplasms | 2 | 2019 | 253 | 0.220 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 4328 | 0.220 |
Why?
|
| Patient Navigation | 1 | 2023 | 33 | 0.220 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2024 | 89 | 0.220 |
Why?
|
| Survival Rate | 9 | 2021 | 12541 | 0.220 |
Why?
|
| Treatment Outcome | 14 | 2023 | 33737 | 0.220 |
Why?
|
| Cell Communication | 2 | 2008 | 512 | 0.220 |
Why?
|
| Fetus | 5 | 2009 | 674 | 0.210 |
Why?
|
| Glutathione Peroxidase | 1 | 2022 | 64 | 0.210 |
Why?
|
| Prospective Studies | 5 | 2023 | 13414 | 0.200 |
Why?
|
| Hospitals, Veterans | 2 | 2015 | 371 | 0.200 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2021 | 316 | 0.200 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2015 | 606 | 0.200 |
Why?
|
| Proportional Hazards Models | 6 | 2018 | 5101 | 0.200 |
Why?
|
| Larynx | 1 | 2023 | 145 | 0.200 |
Why?
|
| Cell Culture Techniques | 4 | 2011 | 575 | 0.200 |
Why?
|
| Disease Models, Animal | 8 | 2021 | 7381 | 0.190 |
Why?
|
| Minority Groups | 2 | 2023 | 328 | 0.190 |
Why?
|
| Head | 1 | 2023 | 248 | 0.190 |
Why?
|
| Deglutition | 2 | 2019 | 187 | 0.190 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 1032 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2023 | 209 | 0.190 |
Why?
|
| Leukoplakia | 1 | 2020 | 6 | 0.190 |
Why?
|
| Adult | 21 | 2024 | 82040 | 0.180 |
Why?
|
| Spouses | 2 | 2019 | 140 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 3917 | 0.180 |
Why?
|
| Laryngeal Diseases | 1 | 2020 | 54 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2015 | 6256 | 0.180 |
Why?
|
| Pharyngeal Diseases | 1 | 2020 | 51 | 0.180 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2020 | 25 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2023 | 197 | 0.180 |
Why?
|
| Cutaneous Fistula | 1 | 2020 | 45 | 0.180 |
Why?
|
| Mandibular Diseases | 1 | 2020 | 50 | 0.170 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 204 | 0.170 |
Why?
|
| Skin | 2 | 2019 | 1271 | 0.170 |
Why?
|
| Extracellular Matrix | 4 | 2011 | 524 | 0.170 |
Why?
|
| Vascularized Composite Allotransplantation | 1 | 2019 | 29 | 0.170 |
Why?
|
| Databases, Genetic | 2 | 2020 | 757 | 0.170 |
Why?
|
| Esomeprazole | 1 | 2019 | 32 | 0.170 |
Why?
|
| HIV | 1 | 2020 | 236 | 0.160 |
Why?
|
| Radiodermatitis | 1 | 2019 | 79 | 0.160 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2019 | 61 | 0.160 |
Why?
|
| Administration, Topical | 1 | 2019 | 258 | 0.160 |
Why?
|
| HIV Infections | 2 | 2022 | 2154 | 0.160 |
Why?
|
| Family Conflict | 1 | 2018 | 24 | 0.160 |
Why?
|
| Sexual Partners | 1 | 2019 | 103 | 0.160 |
Why?
|
| Dermis | 3 | 2007 | 63 | 0.160 |
Why?
|
| Cicatrix | 3 | 2012 | 187 | 0.160 |
Why?
|
| Databases, Nucleic Acid | 1 | 2019 | 116 | 0.160 |
Why?
|
| Interleukin-12 | 1 | 2020 | 267 | 0.160 |
Why?
|
| Oncolytic Viruses | 1 | 2020 | 169 | 0.150 |
Why?
|
| DNA, Mitochondrial | 1 | 2020 | 315 | 0.150 |
Why?
|
| Morbidity | 1 | 2019 | 400 | 0.150 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 70 | 0.150 |
Why?
|
| Fibrosis | 2 | 2019 | 733 | 0.150 |
Why?
|
| Length of Stay | 2 | 2024 | 2007 | 0.150 |
Why?
|
| Citric Acid Cycle | 1 | 2018 | 92 | 0.150 |
Why?
|
| Respiratory Mucosa | 2 | 2010 | 212 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 2 | 2010 | 495 | 0.150 |
Why?
|
| Oncolytic Virotherapy | 1 | 2020 | 239 | 0.140 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2021 | 1690 | 0.140 |
Why?
|
| Self-Management | 1 | 2018 | 105 | 0.140 |
Why?
|
| Thyroidectomy | 2 | 2017 | 489 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 1525 | 0.140 |
Why?
|
| Platinum Compounds | 1 | 2017 | 129 | 0.140 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2353 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2024 | 1458 | 0.140 |
Why?
|
| Genes, p53 | 2 | 2011 | 1140 | 0.140 |
Why?
|
| Comorbidity | 1 | 2022 | 2394 | 0.130 |
Why?
|
| Pharyngeal Muscles | 1 | 2016 | 40 | 0.130 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 751 | 0.130 |
Why?
|
| Interleukin-1 | 2 | 2009 | 475 | 0.130 |
Why?
|
| Antibodies, Bispecific | 1 | 2020 | 282 | 0.130 |
Why?
|
| Carbon Radioisotopes | 1 | 2015 | 124 | 0.130 |
Why?
|
| Metabolism | 1 | 2015 | 50 | 0.130 |
Why?
|
| Incidence | 3 | 2022 | 5824 | 0.130 |
Why?
|
| Tracheal Stenosis | 1 | 2014 | 41 | 0.120 |
Why?
|
| Adenoviridae | 1 | 2020 | 1497 | 0.120 |
Why?
|
| Diet | 2 | 2019 | 1477 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2022 | 1340 | 0.120 |
Why?
|
| Fluoresceins | 1 | 2014 | 74 | 0.110 |
Why?
|
| Carcinogens | 1 | 2015 | 390 | 0.110 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Signal Transduction | 6 | 2023 | 12103 | 0.110 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3345 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2021 | 1336 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1033 | 0.110 |
Why?
|
| Contrast Media | 1 | 2020 | 1499 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 537 | 0.110 |
Why?
|
| Gels | 3 | 2009 | 106 | 0.110 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 340 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1568 | 0.110 |
Why?
|
| Metabolomics | 2 | 2021 | 504 | 0.110 |
Why?
|
| Continuous Positive Airway Pressure | 1 | 2013 | 79 | 0.100 |
Why?
|
| Radiopharmaceuticals | 2 | 2015 | 1341 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2399 | 0.100 |
Why?
|
| Radiation Injuries | 2 | 2020 | 1471 | 0.100 |
Why?
|
| Laser Therapy | 2 | 2007 | 466 | 0.100 |
Why?
|
| Tonsillectomy | 1 | 2013 | 119 | 0.100 |
Why?
|
| DNA Damage | 2 | 2022 | 1989 | 0.100 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 703 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 332 | 0.100 |
Why?
|
| Cell Proliferation | 4 | 2014 | 7238 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2023 | 1903 | 0.100 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 566 | 0.100 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2012 | 198 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2170 | 0.100 |
Why?
|
| Radiotherapy Dosage | 2 | 2016 | 4019 | 0.100 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 38 | 0.100 |
Why?
|
| Heterografts | 1 | 2014 | 738 | 0.100 |
Why?
|
| Neck Dissection | 1 | 2012 | 294 | 0.090 |
Why?
|
| Cell Death | 1 | 2014 | 685 | 0.090 |
Why?
|
| Glucose Transport Proteins, Facilitative | 1 | 2011 | 22 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2014 | 402 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 2400 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2022 | 16689 | 0.090 |
Why?
|
| Texas | 4 | 2020 | 6449 | 0.090 |
Why?
|
| Time Factors | 6 | 2024 | 13006 | 0.090 |
Why?
|
| Radiotherapy | 3 | 2019 | 1857 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 101 | 0.090 |
Why?
|
| Blotting, Western | 4 | 2011 | 3584 | 0.090 |
Why?
|
| Receptors, Prostaglandin | 2 | 2010 | 33 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 3 | 2014 | 5759 | 0.090 |
Why?
|
| Inflammation | 2 | 2019 | 2518 | 0.090 |
Why?
|
| Transplantation, Heterologous | 3 | 2014 | 1054 | 0.090 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2011 | 84 | 0.090 |
Why?
|
| Diabetes Complications | 1 | 2012 | 300 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 30998 | 0.090 |
Why?
|
| Cost of Illness | 1 | 2013 | 505 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2013 | 410 | 0.090 |
Why?
|
| Poverty | 1 | 2013 | 486 | 0.090 |
Why?
|
| Cells, Cultured | 5 | 2010 | 5694 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1840 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 418 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2013 | 260 | 0.080 |
Why?
|
| Risk Factors | 4 | 2020 | 17888 | 0.080 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2011 | 294 | 0.080 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 354 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 4000 | 0.080 |
Why?
|
| Granulation Tissue | 2 | 2005 | 26 | 0.080 |
Why?
|
| Carbon Dioxide | 2 | 2007 | 328 | 0.080 |
Why?
|
| Cyclic AMP | 2 | 2007 | 378 | 0.080 |
Why?
|
| RNA, Messenger | 3 | 2010 | 6390 | 0.080 |
Why?
|
| Mitochondrial Proteins | 1 | 2011 | 379 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2020 | 2178 | 0.080 |
Why?
|
| Connexin 43 | 1 | 2008 | 46 | 0.080 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 584 | 0.080 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2009 | 177 | 0.080 |
Why?
|
| Focal Adhesions | 1 | 2008 | 44 | 0.080 |
Why?
|
| Lasers, Gas | 1 | 2008 | 14 | 0.080 |
Why?
|
| Gap Junctions | 1 | 2008 | 48 | 0.080 |
Why?
|
| Lasers | 1 | 2009 | 235 | 0.080 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 722 | 0.080 |
Why?
|
| Energy Metabolism | 1 | 2014 | 997 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4492 | 0.080 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 907 | 0.070 |
Why?
|
| Phenotype | 2 | 2011 | 6509 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 5315 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2011 | 617 | 0.070 |
Why?
|
| Constriction, Pathologic | 2 | 2005 | 322 | 0.070 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3045 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 2359 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2022 | 927 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 4895 | 0.070 |
Why?
|
| Databases, Factual | 3 | 2020 | 2250 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3597 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2018 | 2828 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 4961 | 0.060 |
Why?
|
| Voice Disorders | 1 | 2005 | 41 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2011 | 1138 | 0.060 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 224 | 0.060 |
Why?
|
| Cell Cycle | 1 | 2011 | 2137 | 0.060 |
Why?
|
| Cell Adhesion | 1 | 2007 | 1028 | 0.060 |
Why?
|
| Splenectomy | 1 | 2005 | 168 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2019 | 318 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2013 | 1240 | 0.060 |
Why?
|
| Anoctamin-1 | 1 | 2024 | 3 | 0.060 |
Why?
|
| Adaptation, Psychological | 2 | 2019 | 787 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2023 | 1903 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2011 | 1710 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2013 | 7914 | 0.060 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2024 | 50 | 0.060 |
Why?
|
| Gingiva | 1 | 2023 | 19 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 1534 | 0.060 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2005 | 211 | 0.060 |
Why?
|
| Statistics, Nonparametric | 2 | 2020 | 984 | 0.050 |
Why?
|
| Proteomics | 1 | 2011 | 1427 | 0.050 |
Why?
|
| Immunogenetics | 1 | 2023 | 18 | 0.050 |
Why?
|
| Pneumothorax | 1 | 2005 | 166 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2003 | 76 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2009 | 2422 | 0.050 |
Why?
|
| Young Adult | 6 | 2020 | 22251 | 0.050 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 62 | 0.050 |
Why?
|
| Skull Base | 1 | 2024 | 225 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 31 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2022 | 33 | 0.050 |
Why?
|
| Cell Survival | 2 | 2014 | 3063 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2024 | 255 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1412 | 0.050 |
Why?
|
| Genomics | 1 | 2013 | 2835 | 0.050 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 40 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2023 | 214 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 2196 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2024 | 477 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2021 | 69 | 0.050 |
Why?
|
| Algorithms | 3 | 2021 | 3891 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2024 | 356 | 0.050 |
Why?
|
| Epigenomics | 1 | 2023 | 273 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2017 | 1430 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 6177 | 0.050 |
Why?
|
| Prevalence | 2 | 2023 | 3404 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 2011 | 2315 | 0.050 |
Why?
|
| Laryngoscopy | 3 | 2008 | 199 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2024 | 7100 | 0.050 |
Why?
|
| Biomarkers | 2 | 2022 | 5051 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 467 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3476 | 0.050 |
Why?
|
| Pharyngectomy | 1 | 2020 | 43 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 545 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2024 | 728 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 2 | 2021 | 2651 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2022 | 331 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2020 | 296 | 0.040 |
Why?
|
| Composite Tissue Allografts | 1 | 2019 | 6 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 1267 | 0.040 |
Why?
|
| Models, Animal | 1 | 2022 | 657 | 0.040 |
Why?
|
| Neck | 1 | 2022 | 395 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2022 | 756 | 0.040 |
Why?
|
| Feeding Methods | 1 | 2019 | 39 | 0.040 |
Why?
|
| Heme Oxygenase-1 | 1 | 2019 | 57 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2011 | 1189 | 0.040 |
Why?
|
| Disease Progression | 1 | 2011 | 6867 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2020 | 232 | 0.040 |
Why?
|
| Hyaluronan Receptors | 1 | 2020 | 248 | 0.040 |
Why?
|
| Models, Biological | 1 | 2007 | 3194 | 0.040 |
Why?
|
| Esophageal Neoplasms | 1 | 2012 | 3240 | 0.040 |
Why?
|
| Swine | 1 | 2003 | 1607 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2022 | 5681 | 0.040 |
Why?
|
| Models, Anatomic | 1 | 2019 | 146 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2024 | 705 | 0.040 |
Why?
|
| Disclosure | 1 | 2019 | 180 | 0.040 |
Why?
|
| Telephone | 1 | 2018 | 160 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 694 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 1076 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2023 | 797 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2023 | 2313 | 0.040 |
Why?
|
| Cytochrome c Group | 1 | 2017 | 70 | 0.040 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 56 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2003 | 2067 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2023 | 1286 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2017 | 55 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 896 | 0.040 |
Why?
|
| Transcription, Genetic | 2 | 2019 | 3339 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2007 | 6224 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7783 | 0.030 |
Why?
|
| Vaccination | 1 | 2023 | 1166 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 875 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1047 | 0.030 |
Why?
|
| Transplantation, Homologous | 1 | 2003 | 3046 | 0.030 |
Why?
|
| Palate, Soft | 1 | 2016 | 31 | 0.030 |
Why?
|
| Laparoscopy | 1 | 2005 | 1302 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2019 | 451 | 0.030 |
Why?
|
| Analog-Digital Conversion | 1 | 2015 | 5 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2020 | 1826 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2021 | 2090 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 1441 | 0.030 |
Why?
|
| Emotions | 1 | 2019 | 560 | 0.030 |
Why?
|
| Enzymes | 1 | 2015 | 71 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 359 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 12 | 0.030 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2015 | 127 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2015 | 4942 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 497 | 0.030 |
Why?
|
| Apoptosis | 2 | 2024 | 7757 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 5162 | 0.030 |
Why?
|
| Ribosomal Protein S6 | 1 | 2014 | 46 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 433 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2015 | 310 | 0.030 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2014 | 52 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2015 | 655 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 2015 | 223 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 727 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2022 | 2098 | 0.030 |
Why?
|
| Protein Transport | 1 | 2016 | 737 | 0.030 |
Why?
|
| Cell Line | 2 | 2011 | 5338 | 0.030 |
Why?
|
| Cognition | 1 | 2019 | 959 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 1942 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 220 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 855 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 895 | 0.030 |
Why?
|
| Propensity Score | 1 | 2016 | 772 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 255 | 0.030 |
Why?
|
| Cellular Senescence | 1 | 2015 | 388 | 0.030 |
Why?
|
| Celecoxib | 1 | 2012 | 198 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 2220 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2018 | 2033 | 0.020 |
Why?
|
| Equipment Design | 1 | 2015 | 1197 | 0.020 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2011 | 51 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2014 | 255 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 62 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 600 | 0.020 |
Why?
|
| Models, Theoretical | 1 | 2015 | 799 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 1553 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 603 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1235 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2014 | 1810 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2011 | 208 | 0.020 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2013 | 562 | 0.020 |
Why?
|
| RNA Interference | 1 | 2014 | 1388 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 5002 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2014 | 1990 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 1093 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 1330 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2011 | 1121 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 407 | 0.020 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2008 | 33 | 0.020 |
Why?
|
| Laryngeal Cartilages | 1 | 2008 | 3 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2019 | 2928 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5457 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7655 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Capillaries | 1 | 2008 | 98 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2011 | 1075 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 1697 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2014 | 1347 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 3485 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 5149 | 0.020 |
Why?
|
| Esophagectomy | 1 | 2012 | 946 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 3557 | 0.020 |
Why?
|
| Time | 1 | 2007 | 183 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2011 | 2156 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2008 | 693 | 0.020 |
Why?
|
| Adolescent | 2 | 2023 | 32767 | 0.020 |
Why?
|
| Laryngeal Mucosa | 1 | 2005 | 5 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2011 | 1516 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1109 | 0.020 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2005 | 8 | 0.020 |
Why?
|
| Regeneration | 1 | 2008 | 284 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2005 | 161 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 4831 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2005 | 69 | 0.020 |
Why?
|
| Blister | 1 | 2005 | 30 | 0.020 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2005 | 78 | 0.020 |
Why?
|
| Pleurodesis | 1 | 2005 | 70 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2011 | 1586 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 4372 | 0.010 |
Why?
|
| Carboplatin | 1 | 2007 | 880 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2012 | 1546 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2010 | 1563 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 741 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2012 | 1933 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2008 | 1642 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1824 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 6441 | 0.010 |
Why?
|
| Brachytherapy | 1 | 2007 | 1005 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 964 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2007 | 2101 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 4130 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 5231 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 4878 | 0.010 |
Why?
|
| Child | 2 | 2005 | 30559 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2005 | 17061 | 0.000 |
Why?
|